Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017
Additionally, Enanta has submitted an abstract to AASLD for consideration of Late Breaking data from its Phase 1 clinical study of EDP-305, including pharmacokinetic and biomarker data, and is planning to have this data announced either in a Late Breaking presentation or poster at The Liver Meeting or as otherwise presented by Enanta.
According to AASLD, the following abstract titles can now be viewed at the AASLD website at https://www.aasld.org/events-professional-development/liver-meeting/program-0/preliminary-program, and the full abstracts will be available in print and posted online on
Poster Presentation,
Session:
#367 – “A novel FXR agonist EDP-305 potently suppresses hepatic stellate cell activation and hepatic fibrosis in chronic mouse models of biliary and metabolic liver disease”
Oral Presentation,
Parallel Session 23: Steatosis and Steatohepatitis: Experimental I
#162 – “Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis”
Poster Presentation,
Session: Steatohepatitis: Experimental
#1988 – “EDP-305 favorably regulates lipoprotein mechanism in vitro”
About Enanta
Royalties and milestone payments from the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170927006300/en/
Source:
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR